Practical implication
Update product labeling to include Lisraya as the first oral treatment for dermatomyositis, ensuring that all marketing and educational materials reflect its approval and associated safety information.
The FDA has granted approval for Lisraya (brepocitinib), marking it as the first oral therapy available for managing dermatomyositis in adults. The approval provides a new option for patients who have historically had limited treatment alternatives. This drug works as a JAK/TYK2 inhibitor and is associated with specific safety warnings.
What changed: Lisraya is now an FDA-approved therapeutic option for dermatomyositis in adults, altering treatment paradigms for this disease.
Why it matters: This approval is critical as it introduces the first effective oral treatment for a disease with historically limited options, positively impacting patient care and treatment outcomes for dermatomyositis.
Practical implication: Update product labeling to include Lisraya as the first oral treatment for dermatomyositis, ensuring that all marketing and educational materials reflect its approval and associated safety information.
View original source
- Source: FDA - What's New Drugs RSS
- Published at source: 2026-08-27T00:00:00.000Z
- Discovered by monitor: 2026-08-27T21:41:39.919Z
Published from the regulator source ingestion pipeline after PV impact triage.
